Flourtown, Pennsylvania Clinical Trials

A listing of Flourtown, Pennsylvania clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 57 clinical trials
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary arterial hypertension (PAH) compared to macitentan 10 mg.

hemodynamic evaluation
patent ductus arteriosus
HIV Infection
atrial septal defect
macitentan
Lankenau Medical Center
 (8.8 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +210 other locations
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine Cyclophosphamide and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

This study will evaluate the efficacy and safety of venetoclax and obinutuzumab (VEN + G) compared with fludarabine + cyclophosphamide + rituximab or bendamustine + rituximab (FCR/BR) in FIT participants (FIT is defined by a cumulative illness rating scale [CIRS]/score of 6 and a normal creatinine clearance of 70 mL/min) …

cyclophosphamide
fludarabine
platelet count
TP53
blood transfusion
Consultants in Medical Oncology and Hematology, P.C.
 (6.2 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +50 other locations
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants

conjugate vaccine
pneumococcal conjugate
Pediatric Medical Associates
 (6.7 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +46 other locations
A Study Evaluating The Safety Tolerability Pharmacokinetics And Efficacy Of Venetoclax In Combination With Atezolizumab Carboplatin And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

A study consisting of a dose-escalation phase and a dose-expansion phase to evaluate the safety, tolerability, pharmacokinetics, and efficacy of venetoclax in combination with atezolizumab, carboplatin, and etoposide.

metastasis
colony stimulating factor
cancer chemotherapy
carboplatin
atezolizumab
Fox Chase Cancer Center
 (7.6 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +15 other locations
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

This study will assess the efficacy and safety of capivasertib plus abiraterone (+prednisone/prednisolone) plus androgen deprivation therapy (ADT) versus placebo plus abiraterone (+prednisone/prednisolone) plus ADT in participants with mHSPC whose tumours are characterised by PTEN deficiency. The intention of the study is to demonstrate that in participants with mHSPC, the …

metastasis
prednisone
antiandrogen therapy
adenocarcinoma
steroid therapy
Research Site
 (7.6 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +106 other locations
A Study Evaluating The Safety Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).

A study evaluating the safety, preliminary efficacy and pharmacokinetics of ipatasertib in combination with atezolizumab and docetaxel in participants with mCRPC previously treated with second-generation AR (Androgen Receptor)-targeted therapy. The study consists of two parts: [1] Part A: Safety run-in cohort of approximately 12 participants; [2] Part B: Expansion cohort …

metastasis
bone scan
adenocarcinoma
atezolizumab
testosterone
Fox Chase Cancer Center
 (7.6 away) Contact site
  • 0 views
  • 16 Feb, 2024
  • +17 other locations
Phase 2 Study of SAR439859 Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)

Primary Objective: To determine whether SAR439859 per os improves progression free survival (PFS) when compared with a endocrine monotherapy of the choice of the physician, in participants with metastatic or locally advanced breast cancer. Secondary Objectives: To compare the overall survival in the 2 treatment arms To assess the objective …

metastasis
immunological adjuvant
endocrine therapy
exemestane
estrogen receptor positive breast cancer
Investigational Site Number 8400001
 (9.0 away) Contact site
  • 0 views
  • 04 Dec, 2020
  • +125 other locations
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease  

This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.

resting tremor
early parkinson's
dopamine
dopamine transporter
parkinsonism
Abington Neurological Associates Willow Grove
 (5.4 away)
  • 0 views
  • 28 Jun, 2022
  • +125 other locations
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have received preoperative chemotherapy and HER2-directed therapy, including trastuzumab followed by surgery, with a finding of residual invasive disease in the breast and/or axillary lymph nodes.

Lankenau Hospital
 (8.8 away) Contact site
  • 0 views
  • 05 Oct, 2021
  • +301 other locations
Test reports v6.12 (DO NOT VISIT)

Test

Abington Neurological Associates Willow Grove
 (5.4 away) Contact site
  • 0 views
  • 02 Mar, 2026
  • +2 other locations